MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Pharmacotherapy for obesity and overweight

Back to weightwatch Blogs list Cancer blog  


Subscribe To Weightwatch RSS Feed  RSS content feed What is RSS feed?

Pharmacotherapy for obesity and overweight




Patients taking anti-obesity drugs will only see modest weight loss and a number of will remain significantly obese or overweight, as per a research studypublished on bmj.com today.

The study, which looked at the long-term effectiveness of anti-obesity medications, observed that three drugs recommended for long-term use - orlistat, sibutramine and rimonabant, reduced weight by less than 5kg (11 pounds). This equated to a loss of less than 5% of total body weight. Guidelines from the National Institute for Clinical Excellence recommend stopping the use of anti-obesity drugs if 5% of total body weight is not lost after three months.



Pharmacotherapy for obesity and overweight

While making changes to lifestyle and diet are recommended as the initial therapy for obesity, the use of anti-obesity drugs is common. Its estimated that in 2005 global sales of anti-obesity drugs reached $1.2billion. Current UK guidelines recommend using drug treatment in addition to making changes in lifestyle if a patient has a body mass index of greater than 30.

The Canadian scientists evaluated the evidence from thirty placebo-controlled trials where adults took anti-obesity drugs for a year or longer. The mean weight of the volunteers in all of the trials was 100kg (15.7 stone). The mean body mass index levels were 35 36.

Professor Raj Padwal and his colleagues found orlistat reduced weight by 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. They also observed that patients taking the weight loss pills were significantly more likely to achieve 5 10% weight loss, in comparison to those who took the placebo.

The health benefits linked to taking the drugs varied. For example, orlistat reduced the occurence rate of diabetes in one trial and all three drugs lowered patients levels of certain types of cholesterol. Adverse effects were recorded with all three drugs, in particular, rimonabant increased the risk of mood disorders such as depression or anxiety. The authors noted that no trials examined rates of death and disease as a result of taking anti-obesity pills. They recommend that trials looking at this should be carried out in the future.

The authors also noted that there were high drop-out levels in all the trials. On average 30 40% of patients failed to complete the trial. They say this suggests that a failure to properly adhere to the therapy could be a major factor limiting the effectiveness of anti-obesity drug treatment.

In an accompanying editorial, Professor Gareth Williams warns of the potential damage to society if anti-obesity drugs are licensed to be sold without prescription. This already happens in the United States, and as Glaxo Smith Kline (GSK) has applied to sell orlistat over the counter throughout Europe, it could happen here. He warns:

Selling anti-obesity drugs over the counter will perpetuate the myth that obesity can be fixed simply by popping a pill and could further undermine the efforts to promote healthy living, which is the only long term escape from obesity.


Posted by: JoAnn    Source




Did you know?
Patients taking anti-obesity drugs will only see modest weight loss and a number of will remain significantly obese or overweight, as per a research studypublished on bmj.com today. The study, which looked at the long-term effectiveness of anti-obesity medications, observed that three drugs recommended for long-term use - orlistat, sibutramine and rimonabant, reduced weight by less than 5kg (11 pounds). This equated to a loss of less than 5% of total body weight. Guidelines from the National Institute for Clinical Excellence recommend stopping the use of anti-obesity drugs if 5% of total body weight is not lost after three months.

Medicineworld.org: Pharmacotherapy for obesity and overweight

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.